Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Recruiting 2Suspended 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Melanoma 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Ovarian Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Skin Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Pleural Effusion, Malignant 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Neuroblastoma 2Myelodysplastic Syndromes 2Mesothelioma, Malignant 2Leukemia, Myeloid 2Leukemia 2Hematologic Neoplasms 2Carcinoma, Merkel Cell 2Anus Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Surveys and Questionnaires 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × aldesleukin × Clear all
NCT06904066 2026-06-05

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics, INC.

Phase 1/2 Recruiting
128 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡